• home
  • contact
  • About Us
  • Opportunity
  • Technology
  • Pipeline
  • Partners
  • Investors
  • News
About Us
  • Mission
  • Who we are
  • Management
  • Board of Directors
  • Scientific Advisory Board
  • Corporate Achievements

We are a product-focused molecular imaging company with broad expertise and IP in the field of brain imaging.

Daniel M. Skovronsky, M.D., Ph.D., President & CEO
Dr. Skovronsky founded Avid Radiopharmaceuticals in late 2004. Dr. Skovronsky has more than 20 peer reviewed publications and several NIH funded grants on Alzheimer’s disease research. Prior to establishing Avid, Dr. Skovronsky served as Scientific Director of High Throughput Screening and Drug Discovery at the Center for Neurodegenerative Disease Research at the University of Pennsylvania. Dr. Skovronsky trained as a resident in Pathology and completed a fellowship in Neuropathology at the Hospital of the University of Pennsylvania. Dr. Skovronsky received his MD and Ph.D. from the University of Pennsylvania and did his undergraduate training in molecular biochemistry at Yale University. Dr. Skovronsky is the recipient of numerous scientific and business awards, and was recently named by the Philadelphia Business Journal as one of their “Forty under Forty” business leaders in the region.

William Hamilton, M.B.A,. Ph.D.
Dr. Hamilton has served on the University of Pennsylvania faculty since 1967 and is the Landau Professor of Management and Technology and the Director of the Jerome Fisher Program in Management and Technology at The Wharton School and the School of Engineering and Applied Science. He also serves as a director of the following life-sciences companies: Neose Technology, Inc. (Nasdaq: NTEC ), NovaDel Pharma, Inc. (Amex: NVD) and Neuronyx (a privately-held leader in stem cell technologies), and previously served as a Director of Centocor, Inc. prior to its acquisition by Johnson & Johnson. Dr. Hamilton received his B.S., M.S. (chemical engineering) and M.B.A. from the University of Pennsylvania and his Ph.D. in applied economics from the London School of Economics.

Gary J. Kurtzman, M.D.
Dr. Kurtzman is Managing Director in the Life Sciences Group at Safeguard Scientifics, Inc. (NYSE: SFE), a provider of growth capital for entrepreneurial and innovative life sciences and technology companies, where he is responsible for identifying and partnering with companies focused on molecular diagnostics, medical devices, regenerative medicine and specialty pharmaceuticals services. As part of Safeguard’s Life Sciences Group, Dr. Kurtzman brings more than 17 years of experience in operations and investments, leveraging his expertise to enable businesses to grow their products and services, as well as to discover new partnering potential. Dr. Kurtzman currently serves on the board of directors for Safeguard Scientifics’ partner companies: Advanced BioHealing, Alverix, Avid Radiopharmaceutics, Molecular Biometrics, NuPathe and Tengion. Dr. Kurtzman was previously managing director of BioAdvance, an early stage life sciences investor, and held various positions at Pluvita Corporation, Genovo and Avigen, and Gilead Sciences.

Dr. Kurtzman is a board-certified internist with a hematology sub-specialty. He is the author of more than 40 peer reviewed scientific publications, reviews and book chapters and the inventor on 18 issued U.S. patents. He is currently a lecturer in Health Care Management at The Wharton School of the University of Pennsylvania where he teaches bioentrepreneurship. Dr. Kurtzman received his BS from Stanford University and his MD from Washington University and post-doctoral training at the National Heart, Lung and Blood Institute and Stanford University.

Ernest Mario, Ph.D.
Dr. Mario is chairman and CEO of Capnia, a developer of novel therapeutic products based on a proprietary medical gas delivery system. Dr. Mario is the former Chairman and CEO of Reliant Pharmaceuticals prior to its sale to GlaxoSmithKline, and he serves on the boards of directors of Boston Scientific, Maxygen, Inc., Alexza Pharmaceuticals and Pharmaceutical Product Development, Inc. Previously Dr. Mario was Chairman and CEO of Apothogen, Inc. before it was acquired by IntraBiotics Pharmaceuticals, Inc. in 2002. He then held the position of Chairman of IntraBiotics until April 2003. From 1993 to 2001 Dr. Mario served as CEO of ALZA Corporation, and from 1989 to 1993 he served as CEO of Glaxo Holdings plc. Dr. Mario is a past Chairman of the American Foundation for Pharmaceutical Education and serves as an advisor to the pharmacy schools at the University of Maryland, the University of Rhode Island and The Ernest Mario School of Pharmacy at Rutgers University. Dr. Mario holds a B.S. in Pharmacy from Rutgers, and an M.S. and a Ph.D. in Physical Sciences from the University of Rhode Island. He is the recipient of the 2007 Remington Medal, the highest honor of the American Pharmacists Association.

Matthew Rhodes-Kropf, Ph.D.
Dr. Rhodes-Kropf serves at the Columbia University School of Business as an Associate Professor of Finance. He specializes in Mergers & Acquisitions and venture capital, and has developed path breaking theories of pricing and participation in the VC markets. Dr. Rhodes-Kropf founded and manages the venture fund RK Ventures and is actively involved in several early stage companies. Dr. Rhodes-Kropf received his B.S., M.A. and Ph.D. from Duke University.